Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy.

ABSTRACT:

Purpose

Few studies with a large sample size are available on patients with metabolic syndrome (MetS) receiving neoadjuvant treatment (NAT) for breast cancer. This study aimed to investigate the impact of MetS on the prognosis of patients with breast cancer undergoing NAT.

Methods

The data of patients with breast cancer receiving NAT at our center from January 2017 to December 2019 were retrospectively analyzed. A chi-square test and logistic regression model were applied to ascertain the factors associated with MetS and pathological complete response (pCR). The Cox proportional risk model was employed for univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS).

Results

Of the 910 patients enrolled, 164 (18.0%) were diagnosed with

SUBMITTER: Ma Y 

PROVIDER: S-EPMC11660380 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature